1. Home
  2. RNAZ
  3. RNAZ News

Latest TransCode Therapeutics Inc. (RNAZ) News on November 17, 2025

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
RNAZ

PR Newswire

a month ago

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

RNAZ

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Late Afternoon

RNAZ

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Wednesday Afternoon

RNAZ

MT Newswires

a month ago

Sector Update: Health Care

RNAZ

MT Newswires

a month ago

TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
RNAZ

PR Newswire

a month ago

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
RNAZ

PR Newswire

6 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
RNAZ

PR Newswire

6 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
RNAZ

PR Newswire

6 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
RNAZ

PR Newswire

6 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
RNAZ

NewMediaWire

7 months ago

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
RNAZ

PR Newswire

7 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug
RNAZ

Benzinga

7 months ago

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
RNAZ

PR Newswire

7 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
RNAZ

Zacks

7 months ago

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
RNAZ

PR Newswire

8 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
RNAZ

PR Newswire

8 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
RNAZ

PR Newswire

8 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138
RNAZ

Clinical Trials Arena

8 months ago

SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138

RNAZ

MT Newswires

8 months ago

TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
RNAZ

PR Newswire

8 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting
RNAZ

PR Newswire

9 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
RNAZ

PR Newswire

9 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
RNAZ

PR Newswire

9 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
RNAZ

PR Newswire

10 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
RNAZ

PR Newswire

10 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
RNAZ

PR Newswire

a year ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Transcode Therapeutics issues 21.2M shares at 37.7c in private placement
RNAZ

TipRanks

a year ago

Transcode Therapeutics issues 21.2M shares at 37.7c in private placement

RNAZ

MT Newswires

a year ago

TransCode Therapeutics to Sell Securities Worth $8 Million in Private Placement

TransCode Therapeutics, Inc. Announces $8 Million Private Placement
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Transcode Therapeutics announces 1-for-33 reverse stock split
RNAZ

TipRanks

a year ago

Transcode Therapeutics announces 1-for-33 reverse stock split

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

TransCode Therapeutics Open Letter to Shareholders
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. Announces Closing of Public Offering
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics, Inc. Announces Pricing of Public Offering
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
RNAZ

GlobeNewswire

a year ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
RNAZ

GlobeNewswire

a year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Open Letter to Shareholders
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports 2023 Results; Provides Business Update
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
RNAZ

PR Newswire

2 years ago

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
RNAZ

GlobeNewswire

2 years ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

RNAZ

Business Wire

2 years ago

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

SU Group Holdings Limited Announces Closing of Initial Public Offering
RNAZ

PR Newswire

2 years ago

SU Group Holdings Limited Announces Closing of Initial Public Offering

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode (RNAZ) Down 50% on Issue of New Common Stock
RNAZ

Zacks

2 years ago

TransCode (RNAZ) Down 50% on Issue of New Common Stock

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
RNAZ

GlobeNewswire

2 years ago

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

RNAZ

Business Wire

2 years ago

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

RNAZ

Business Wire

2 years ago

Xos and ElectraMeccanica Announce Proposed Combination to Accelerate Xos’ Leadership Position in Manufacturing Commercial Electric Vehicles for Major U.S. Fleet Customers

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

2 Radio Frequency Stocks to Watch in a Challenging Industry
RNAZ

Zacks

2 years ago

2 Radio Frequency Stocks to Watch in a Challenging Industry

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
RNAZ

Business Wire

2 years ago

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
RNAZ

GlobeNewswire

2 years ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

3 EV Stocks to Sell in January Before They Crash and Burn
RNAZ

InvestorPlace

2 years ago

3 EV Stocks to Sell in January Before They Crash and Burn

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

RNAZ

Business Wire

2 years ago

Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
RNAZ

Simply Wall St.

2 years ago

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
RNAZ

PR Newswire

2 years ago

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

The Dixie Group Reports the Completion of The Sale and Leaseback of Its Facility in Adairsville, GA
RNAZ

ACCESSWIRE

2 years ago

The Dixie Group Reports the Completion of The Sale and Leaseback of Its Facility in Adairsville, GA

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
RNAZ

GlobeNewswire

2 years ago

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
RNAZ

GlobeNewswire

2 years ago

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
RNAZ

GlobeNewswire

2 years ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Cenntro Electric Group Announces Delivery of More than 250 Autonomous Driving Delivery Vehicles
RNAZ

Business Wire

2 years ago

Cenntro Electric Group Announces Delivery of More than 250 Autonomous Driving Delivery Vehicles

Leafly 2023 Cannabis Strain of the Year is "Permanent Marker"
RNAZ

Business Wire

2 years ago

Leafly 2023 Cannabis Strain of the Year is "Permanent Marker"

CORRECTION – Xcel Brands, Inc. and Fashion Icon Christie Brinkley form Joint Venture
RNAZ

GlobeNewswire

2 years ago

CORRECTION – Xcel Brands, Inc. and Fashion Icon Christie Brinkley form Joint Venture

Air Industries Group Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q
RNAZ

Business Wire

2 years ago

Air Industries Group Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q

EV Roundup: NSANY's $1.4B Outlay, VWAGY's China-Specific EV Platform & More
RNAZ

Zacks

2 years ago

EV Roundup: NSANY's $1.4B Outlay, VWAGY's China-Specific EV Platform & More

Market Cool On Sarcos Technology and Robotics Corporation's (NASDAQ:STRC) Revenues
RNAZ

Simply Wall St.

2 years ago

Market Cool On Sarcos Technology and Robotics Corporation's (NASDAQ:STRC) Revenues

180 Degree Capital Corp. (NASDAQ:TURN) Q3 2023 Earnings Call Transcript
RNAZ

Insider Monkey

2 years ago

180 Degree Capital Corp. (NASDAQ:TURN) Q3 2023 Earnings Call Transcript

RNAZ

Business Wire

2 years ago

Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
RNAZ

GlobeNewswire

2 years ago

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

RNAZ

Business Wire

2 years ago

Boxlight Reports Third Quarter 2023 Financial Results

Boxlight (NASDAQ:BOXL) Shareholders Will Want The ROCE Trajectory To Continue
RNAZ

Simply Wall St.

2 years ago

Boxlight (NASDAQ:BOXL) Shareholders Will Want The ROCE Trajectory To Continue

Bandwidth Inc. (NASDAQ:BAND) Q3 2023 Earnings Call Transcript
RNAZ

Insider Monkey

2 years ago

Bandwidth Inc. (NASDAQ:BAND) Q3 2023 Earnings Call Transcript

Intellinetics Names Michael N. Taglich to Board of Directors
RNAZ

Business Wire

2 years ago

Intellinetics Names Michael N. Taglich to Board of Directors

Airspan Partners With Prospecta Utilities to Deliver 5G mmWave FWA Across Australia
RNAZ

Business Wire

2 years ago

Airspan Partners With Prospecta Utilities to Deliver 5G mmWave FWA Across Australia

ACRES COMMERCIAL REALTY CORP. ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID J. BRYANT AND NAMES ELDRON C. BLACKWELL AS SUCCESSOR
RNAZ

PR Newswire

2 years ago

ACRES COMMERCIAL REALTY CORP. ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID J. BRYANT AND NAMES ELDRON C. BLACKWELL AS SUCCESSOR

Aptevo to Present at Bio-Europe Conference
RNAZ

ACCESSWIRE

2 years ago

Aptevo to Present at Bio-Europe Conference

Share on Social Networks: